This invention relates to sustained release dosage forms comprising {l-{ l-[3-fluoro-2- (trifluoromethyl)isonicotinoyl]piperidin-4-yl}- 3-[4-(7H-pyrrolo[2,3- d]pyrimidin-4-yl)-lH-pyrazol-l-yl]azetidin-3-yl}acetonitrile, or a pharmaceutically acceptable salt thereof, and doses and methods related thereto.